Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion
Abstract Objective PF-06438179/GP1111 (PF-SZ-IFX) is an infliximab biosimilar. We evaluated the extended in-use physicochemical and biological stability of PF-SZ-IFX upon preparation for intravenous infusion. Methods Two batches of PF-SZ-IFX were reconstituted to a concentration of 10 mg/mL and subs...
Saved in:
Main Authors: | Maja Vimpolsek (Author), Marie Gottar-Guillier (Author), Emmanuel Rossy (Author) |
---|---|
Format: | Book |
Published: |
Adis, Springer Healthcare,
2019-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Infusion reaction to infliximab biosimilar after transitioning from infliximab
by: Reem Kashlan, MPH, et al.
Published: (2021) -
Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
by: Subedi S, et al.
Published: (2019) -
Case Report: Infusion-Related Reactions to Intravenous Infliximab and Subcutaneous Ustekinumab in Pediatric Crohn's Disease
by: Toshihiko Kakiuchi, et al.
Published: (2021) -
In-Use Stability of SB12 (Eculizumab, Soliris Biosimilar) Diluted in Saline and Dextrose Infusion Solution after an Extended Storage Period
by: Minji Tak, et al.
Published: (2023) -
Psoriasiform paradojic reaction associated with infliximab infusion
by: Lorena De Agustín Sierra
Published: (2017)